Related Experiment Videos
Postresection irradiation for T2 N0 M0 non-small cell carcinoma: a prospective, randomized study
J J Lafitte1, M E Ribet, B M Prévost
1Department of Pneumology, Hôpital Calmette, Centre Hospitalier Régional Universitaire, Lille, France.
The Annals of Thoracic Surgery
|September 1, 1996
Summary
Postoperative irradiation did not significantly improve survival for Stage I T2 N0 non-small cell lung carcinoma. This cancer stage often leads to distant metastasis, suggesting a need for systemic adjuvant therapy.
Area of Science:
- Oncology
- Thoracic Surgery
- Radiation Oncology
Background:
- Stage I T2 N0 non-small cell lung carcinoma (NSCLC) prognosis is comparable to stage II T1 N1 NSCLC.
- Hypothesized that T2 N0 M0 tumors have more overlooked locoregional sites than T1 N0 M0 tumors.
- Investigated potential benefit of postresection irradiation for T2 N0 NSCLC.
Purpose of the Study:
- To evaluate the efficacy of postoperative irradiation in Stage I T2 N0 non-small cell lung carcinoma.
- To compare survival and recurrence rates between irradiated and non-irradiated groups.
Main Methods:
- 132 patients with T2 N0 M0 NSCLC were randomized to receive or not receive postresection irradiation (1985-1991).
- Follow-up was conducted until October 1995.
- Statistical analysis included volume, location, cell type, survival, and recurrence.
Main Results:
- Overall 5-year survival was 44.2% (49 of 132 patients alive at study close).
- No significant difference in survival or recurrence was observed between irradiated and non-irradiated groups.
- Distant metastasis was the primary cause of death, with no recurrence-free survivors beyond 5 years for tumors invading the visceral pleura.
Conclusions:
- Stage I T2 N0 M0 NSCLC frequently develops distant metastases.
- Radical resection alone yields moderate results for this tumor stage.
- Further research into stratified systemic adjuvant therapies is recommended to improve outcomes.